{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Sibrotuzumab",
  "nciThesaurus": {
    "casRegistry": "216669-97-5",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A humanized monoclonal antibody (MoAb) against human fibroblast activation protein (FAP). FAP is a 95 kDa cell surface glycoprotein and an inducible tumor stromal antigen of epithelial cancers and of a subset of soft tissue sarcomas. FAP shows a very limited distribution pattern in normal tissues, thereby sibrotuzumab has possible diagnostic and therapeutic applications in epithelial cancers.",
    "fdaUniiCode": "552U6E1NIW",
    "identifier": "C156438",
    "preferredName": "Sibrotuzumab",
    "semanticType": "Amino Acid, Peptide, or Protein",
    "subclassOf": [
      "C129822",
      "C20401"
    ],
    "synonyms": [
      "HuMoAb F19",
      "Humanized F19 Monoclonal Antibody",
      "SIBROTUZUMAB",
      "Sibrotuzumab"
    ]
  }
}